NCT06243198

A Study to Investigate the Safety and Pharmacokinetics of Lebrikizumab in Healthy Chinese Participants

A Phase 1, Participant- and Investigator-blinded, Randomized, Single-dose Study to Investigate the Safety and Pharmacokinetics of Lebrikizumab in Healthy Chinese Participants

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 24 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years – 65 Years
• Healthy volunteers: Accepted

Summary

The main purpose of this study is to determine the tolerability and side effects related to lebrikizumab comparing with placebo given as a single dose administered under the skin to healthy Chinese participants. The study will also assess how fast lebrikizumab gets into the blood stream and how long the body takes to get rid of it. Each enrolled participant will receive a single dose of either Lebrikizumab or placebo. For each participant, the total duration of the study will be approximately up to 21 weeks, including screening period.

Conditions

• Healthy

Interventions

Type	Name	Description
DRUG	Lebrikizumab	Administered subcutaneously (SC)
DRUG	Placebo	Administered subcutaneously (SC)

Timeline

• Start date: 2024-03-28
• Primary completion: 2024-09-03
• Completion: 2024-09-03
• First posted: 2024-02-06
• Last updated: 2025-09-12
• Results posted: 2025-09-12

Locations

1 site across 1 country: China

Regulatory

• FDA-regulated drug study